- George Medicines, in partnership with Piramal Pharma Solutions, has developed WIDAPLIK, the first FDA-approved triple combination drug for hypertension to be used as initial therapy.
- The collaboration began in 2018 and involved formulation development and manufacturing at Piramal’s facilities in India.
George Medicines, a late-stage biopharma company, has partnered with Piramal Pharma Solutions (PPS), a global CDMO, to develop WIDAPLIK, a new drug for the treatment of hypertension in adults. The therapy has received FDA approval, marking it as the first and only triple combination medication authorised for use as an initial treatment in patients likely to require multiple drugs to reach blood pressure goals.
WIDAPLIK combines telmisartan, amlodipine, and indapamide in a single pill and has been developed in three doses: 10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg. Two of these doses are lower than those currently available in single pill combinations, offering patients early access to the benefits of a multi-mechanism approach with an established safety profile.
The collaboration between George Medicines and PPS began in December 2018 with formulation work at Piramal’s development site in Ahmedabad, India. By June 2020, the project had progressed to validation and manufacturing at Piramal’s Pithampur facility. PPS’s technical expertise in drug development and contract manufacturing supported the path to FDA approval.
“This achievement highlights the value that Piramal Pharma Solutions delivers to its clients and the patients they serve,” said Peter DeYoung, CEO, Piramal Global Pharma. “We are excited to deepen our collaboration with George Medicines, expanding access to transformative treatment options like WIDAPLIK to support our mission and enhance patient outcomes on a global scale.”
